Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-10258
Authors: Bougrine, Houda
Ammar, Achraf
Salem, Atef
Trabelsi, Khaled
Jahrami, Haitham
Chtourou, Hamdi
Souissi, Nizar
Title: Optimizing short-term maximal exercise performance : the superior efficacy of a 6 mg/kg caffeine dose over 3 or 9 mg/kg in young female team-sports athletes
Online publication date: 2-Apr-2024
Year of first publication: 2024
Language: english
Abstract: Caffeine (CAF) is among the most extensively researched dietary supplements worldwide. However, little is known about the relationship between dosage and performance enhancement, particularly in female athletes. This study aimed to explore the effects of three different CAF dosages (3 mg·kg−1, 6 mg·kg−1, and 9 mg·kg−1) on high-intensity exercise and the prevalence of undesirable side effects related to these doses among female team-sports athletes. All participants (n = 16; age: 16.9 ± 0.6 y; height: 1.64 ± 0.1 m; BMI: 21.6 ± 1.5 kg·m−2) were mild CAF consumers. This study had a randomized, crossover, double-blind design in which each athlete performed four experimental sessions after ingesting either a placebo (PLAC), 3 mg·kg−1 CAF (CAF-3), 6 mg·kg−1 CAF (CAF-6), or 9 mg·kg−1 of CAF (CAF-9), with an in-between washout period of at least 72 h. In each experimental session, 60 min after ingesting the capsules, participants underwent a countermovement jumps test (CMJ), modified agility t-test (MATT), repeated sprint ability (RSA) test, and a rating of perceived exertion (RPE) and completed the CAF side effects questionnaire. Our findings revealed that in comparison to the PLAC condition, the MATT, RSAmean, and RSAbest performances were significantly greater only under the CAF-6 and CAF-9 conditions. Although the RPE scores remained unchanged, CMJ performance improved under all CAF conditions. All the performance outcomes were better for the CAF-6 and CAF-9 conditions than for the CAF-3 condition. Notably, no significant difference between the CAF-6 and CAF-9 conditions was observed for any of these parameters despite the highest incidence of side effects being noted for the CAF-9 condition. In summary, our findings highlight the recommendation for a moderate CAF dosage of 6 mg·kg−1 rather than 3 or 9 mg·kg−1 to enhance various aspects of short-term maximal performance in mild-CAF-consumer female team-sports athletes while mitigating the occurrence of adverse CAF side effects.
DDC: 796 Sport
796 Athletic and outdoor sports and games
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 02 Sozialwiss., Medien u. Sport
Place: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-10258
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY
Information on rights of use: https://creativecommons.org/licenses/by/4.0/
Journal: Nutrients
16
5
Pages or article number: 640
Publisher: MDPI
Publisher place: Basel
Issue date: 2024
ISSN: 2072-6643
Publisher DOI: 10.3390/nu16050640
Appears in collections:DFG-491381577-G

Files in This Item:
  File Description SizeFormat
Thumbnail
optimizing_shortterm_maximal_-20240402101601566.pdf1.72 MBAdobe PDFView/Open